Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in more than 40 countries.  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news